Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

FDA issues draft-guidance on accreditation of third-party reviewers for 510(k)s and final guidance for surgical ablation devices. More regulatory news.

You may also be interested in...



FDA To Issue UDI Database Draft Guidance In March

The draft guidance will serve as a user’s guide to the soon-to-be-released unique device identifier database, providing definitions for the device elements and attributes that companies have to submit to the database.

As GHTF Ends, Industry Cautiously Optimistic On Future Harmonization Progress Under IMDRF

As the Global Harmonization Task Force held its final meeting last week in Tokyo, members of industry met separately to discuss how GHTF’s work will be carried on by the International Medical Device Regulators Forum.

FDA’s UDI Draft Rule Details Device Marking, Database Submission Mandates

The long-anticipated proposal maps out a unique device identifier system that FDA says will be crucial to the future of post-market safety surveillance, recall management and safety alerts. The effort also will help reduce medical errors and bring an array of other benefits, stakeholders say.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel